奈达铂、顺铂在宫颈癌同步放化疗中的临床对比

Clinical Comparison of Nedaplatin, Cisplatin in Cervical Cancer Concurrent Chemoradiotherapy

目的研究奈达铂以及顺铂应用于宫颈癌同步放化疗中发挥的作用。方法选择48例中晚期宫颈癌化疗患者,对照组24例采用奈达铂实施同步放化疗,观察组24例应用顺铂开展同步放化疗。结果两组患者总体治疗有效率差异无统计学意义(P>0.05);观察组血小板减少发生率为34.2%,低于对照组的63.2%(P<0.05);观察组肝肾功能损害发生率高于对照组(P<0.05)。结论针对宫颈癌中晚期患者,选择奈达铂以及顺铂进行同步放化疗均能够取得良好疗效,两种药物所引发的临床不良反应存在一定差异。

Objective To study the nedaplatin and cisplatin used in cervical cancer chemoradiation plays the role of the work. Methods 48 patients with locally advanced cervical cancer chemotherapy, the control group 24 cases using nedaplatin chemoradiation, observation group of 24 cases with cisplatin in concurrent chemoradiotherapy. Results Two groups of patients overall treatment efficient differences had no statistical significance （P〉0.05）. Thrombocytopenia rate was 34.2%,the observation group was obviously less than 63.2% in the control group （P〈0.05）, The incidence of liver and kidney function damage observation group was obviously higher than that of control group （P〈0.05）. Conclusion For patients with cervical cancer middle-late, nedaplatin, choose platinum and cisplatin chemoradiation can achieve good curative effect, the two drugs clinical adverse reactions caused by there exist certain differences.